BiovelocITA, the Italian biotech accelerator, launches two companies, one against diabetes, the other against cancer
Two research project collaborations – one in diabetes and one in oncology – have been launched, with a total investment of €2.5 million. These are the first projects launched by BiovelocITA, the Italian biotech accelerator launched last year by the chemist and entrepreneur Silvano Spinelli, Gabriella Camboni and the venture capital firm Sofinnova Partners. The collaborations were sealed with Enthera, a start-up that will develop therapies to treat diabetes, and a research project from the Milanese IFOM (the FIRC Institute of Molecular Oncology) for the development of anti-cancer drugs.
